Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

15
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
15
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

14
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hook effect for ferritin immunoassays: implications for clinical practice.

Clinical chemistry and laboratory medicine·2025
Same author

Validation of Dried Blood Spot Immunoreactive Trypsinogen as a Biomarker of Exocrine Pancreas Function in Children With Pancreas Disease.

The American journal of gastroenterology·2025
Same author

New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory.

Clinical biochemistry·2024
Same author

Self-management intervention for patients following hospitalization for acute exacerbation of chronic obstructive pulmonary disease (AECOPD): A pilot randomized controlled trial.

Nursing & health sciences·2024
Same author

Behavioral Weight Loss Interventions for Overweight and Obese Cardiac Rehabilitation Patients: A Systematic Review.

Western journal of nursing research·2023
Same author

Analytical Unreliability of 25 Hydroxy Vitamin D Measurements in Pre-Term Neonates.

The journal of applied laboratory medicine·2023
Same journal

Cardiovascular disease and miRNA.

Advances in clinical chemistry·2026
Same journal

RNA biomarkers in antidoping.

Advances in clinical chemistry·2026
Same journal

Biomarkers for assessing magnesium status.

Advances in clinical chemistry·2026
Same journal

Advances in microfluidic extracellular vesicle technology.

Advances in clinical chemistry·2026
Same journal

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026
Same journal

Biomarkers in heart failure.

Advances in clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

849

Advances in preeclampsia testing.

Jessica J Miller1, Victoria Higgins2, Annie Ren3

  • 1Dynacare, Brampton, ON, Canada.

Advances in Clinical Chemistry
|November 16, 2023
PubMed
Summary
This summary is machine-generated.

Preeclampsia biomarkers like placental growth factor (PlGF) and soluble FMS like tyrosine kinase 1 (sFlt-1) offer improved diagnostic accuracy. These markers are crucial for timely identification and management of preeclampsia, enhancing maternal and fetal safety.

Keywords:
Clinical practice guidelinesDiagnostic performanceLaboratory testingPlacental growth factor (PlGF)PreeclampsiaSoluble FMS like tyrosine kinase (sFlt-1)

More Related Videos

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

10.7K
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

15.9K

Related Experiment Videos

Last Updated: Jul 11, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

849
The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

10.7K
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

15.9K

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Clinical Chemistry

Background:

  • Preeclampsia is a serious hypertensive disorder causing significant maternal and fetal complications.
  • Current diagnostic methods, including hypertension, proteinuria, and liver enzyme tests, lack specificity and sensitivity.
  • There is a critical need for reliable biomarkers for early and accurate preeclampsia detection.

Purpose of the Study:

  • To review the clinical characteristics and pathogenesis of preeclampsia, focusing on angiogenic factors.
  • To examine current clinical practice guidelines and laboratory testing recommendations for preeclampsia diagnosis.
  • To evaluate available placental growth factor (PlGF) and soluble FMS like tyrosine kinase 1 (sFlt-1) assays for clinical utility.

Main Methods:

  • Review of clinical characteristics of preeclampsia.
  • Analysis of the role of angiogenic factors (PlGF, sFlt-1) in preeclampsia pathogenesis.
  • Evaluation of clinical practice guidelines for diagnostic criteria.
  • Assessment of methodologies, analytical performance, and clinical values of PlGF and sFlt-1 assays.

Main Results:

  • Preeclampsia diagnosis relies on non-specific clinical signs and lab tests.
  • Angiogenic factors like PlGF and sFlt-1 are implicated in preeclampsia pathogenesis.
  • Available PlGF and sFlt-1 assays show varying degrees of analytical performance and clinical utility.

Conclusions:

  • Biomarkers such as PlGF and sFlt-1 hold promise for improving preeclampsia diagnosis and management.
  • Further research is needed to optimize analytical and clinical aspects of these biomarkers.
  • Enhanced diagnostic tools are essential for reducing maternal and fetal morbidity and mortality associated with preeclampsia.